• CAS号
  • HIT ID
  • 供应商货号
  • SMILES
  • 化合物库

购物车
0
  2. 结构式搜索
  3. HIT220913254
有库存
HIT220913254
 sdf 文件
结构编辑
类似物检索
HIT220913254
  • HIT ID:HIT220913254
  • Cas No:139751-07-8
  • 常用名:Noberastine citrate
  • IUPAC:2-hydroxypropane-1,2,3-tricarboxylic acid; N-{3-[(5-methylfuran-2-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl}piperidin-4-amine
    IUPAC:2-hydroxypropane-1,2,3-tricarboxylic acid; N-{3-[(5-methylfuran-2-yl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl}piperidin-4-amine
  • InChI key:InChIKey=VXIJMTRTCJNTMW-UHFFFAOYSA-N
  • 分子式:C23H29N5O8
  • 分子量:503.512
  • 氢键供体数 (HBD):
  • 氢键受体数 (HBA):
  • LogP:
  • SMILES:OC(=O)CC(O)(CC(O)=O)C(O)=O.Cc1ccc(Cn2c(NC3CCNCC3)nc3cccnc23)o1
    SMILES:OC(=O)CC(O)(CC(O)=O)C(O)=O.Cc1ccc(Cn2c(NC3CCNCC3)nc3cccnc23)o1
  • Noberastine citrate, a histamine H1 antagonist, has potent and specific peripheral antihistaminic activity. Noberastine, a furan derivative of nor-astemizole (an astemizole metabolite), has been shown to have a more rapid onset, and shorter duration of action than astemizole with peak antihistaminic activity at 4h following ingestion. Noberastine is rapidly absorbed and the peak plasma levels are obtained within 2 h of oral dosing. In preclinical studies Noberastine has been shown to lack central nervous system effects. After subacute (steady-state) administration of noberastine, there was increasing inhibition of weal and flare formation with higher doses of the drug. The 30 mg daily dose showed maximum antihistaminic effects.
市场产品/服务共显示1个结果
  • 供应商
    TargetMolSC
    规格
    货期
    1-2周
    纯度
    -
    ¥ 10,600.00
    1

寻找合适的化合物库

您无法确定哪种化合物库最适合您的项目？或者您需要定制解决方案？Anymole随时为您提供帮助。
电话：400820-0310
合作：info@screeningcompound.com
技术支持：tech@screeningcompound.com
客服：service@screeningcompound.com
TargetMol | Target Loading
正在加载 ~
常用功能
使用指南化合物搜索在线客服返回顶层